Management can confirm that the projected +11 MSEK in Nordic turnover for Q1 is well within reach, representing the highest quarterly sales to date in the region. Furthermore, the December tender in Sweden for the new products Amlodipine and Imatinib was successfully secured.
Over the next four months, we plan to launch Atorvastatin, Darunavir as well as additional strengths of Amlodipine and Sertraline. In addition to the established products above we will proceed to launch Pazopanib and Dimethyl Fumarate as soon as regulatory exclusivities and patents allow us.
The company has optimized its leadership structure, generating measurable cost savings while maintaining strong execution capabilities across the Nordic region. Despite the inherent volatility of monthly tenders, Newbury’s remains well positioned for continued growth.
Leadership Update: Fredrik Hellqvist promoted to GM Nordic
To support the next phase of regional expansion, Fredrik Hellqvist has been promoted from VP Sales & Marketing to General Manager Nordic. Fredrik, who has been with Newbury Pharmaceuticals since 2021, will assume responsibility for the company’s operations in the Nordic region. His leadership and deep market expertise will be central as the product portfolio and tender activity accelerate.